Rezafungin Prophylaxis in Liver Transplant

Launched by FERNANDA P SILVEIRA, MD, MS · Jan 8, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new medication called rezafungin to see if it can help prevent serious fungal infections in people who have recently received a liver transplant. Fungal infections can be a significant risk for these patients, and the study will compare the outcomes of those who receive rezafungin to those who had a liver transplant in the last two years without this medication.

To be eligible for the trial, participants must be at least 18 years old and have received a liver transplant. They should have one or more factors that increase their risk for fungal infections, such as having a living donor transplant or undergoing complicated surgery. However, individuals who are expected not to survive beyond seven days after the transplant or who have a history of allergy to similar medications cannot participate. This trial is not yet recruiting, but once it starts, participants will have the opportunity to contribute to important research that could improve care for future liver transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Liver transplant recipient
• • 18 years of age or older
• • ≥1 risk factor(s) for IFI: living donor transplant, retransplantation, complicated operations (based on duration of transplant and number of blood products required in the peri-transplant period), choledochojejunostomy anastomosis, or peri-operative Candida colonization, recent Candida infection, renal replacement therapy post-transplant, and reoperation within the first 90 days of transplant.
• Exclusion Criteria:
• • Participants who are perceived not to survive past 7 days after transplant
• • Participants who elect not to participate in the prospective trial
• • Participants who had active candidiasis at the time of transplant
• • Participants with a history of allergy to an echinocandin
• • Participants who are pregnant.